Long-term Impact of Overweight/Obesity and Hypertension on Cardiovascular Risk in Middle-aged and Elderly Adults: A Cohort Study
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 31,080
- 试验地点
- 1
- 主要终点
- Percentage of participants with major adverse cardiovascular events (MACEs)
研究概览
简要总结
Long-term Impact of Overweight/Obesity and Hypertension on Cardiovascular Risk in Middle-aged and Elderly Adults
详细描述
Overweight and obesity are major risk factors associated with the development of hypertension, poor blood pressure control, and adverse cardiovascular outcomes. However, evidence regarding the long-term impact of overweight/obesity and hypertension on cardiovascular risk in middle-aged and elderly populations remains limited. Therefore, the present study aims to evaluate the long-term effects of overweight/obesity and hypertension on cardiovascular risk in middle-aged and elderly adults.Additionally, a subgroup analysis will be conducted in participants with sarcopenia to assess the influence of blood pressure on prognosis, exploring potential interactions between muscle loss, hypertension, and cardiovascular outcomes.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Other
入排标准
- 年龄范围
- 45 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Ages of ≥ 45 years
- •Participants from routine health examinations at Tongzhou Community Health Service Center
- •Availability for follow-up until 2026
- •No major barriers to provide written consent
排除标准
- 未提供
结局指标
主要结局
Percentage of participants with major adverse cardiovascular events (MACEs)
时间窗: 2021-2026
Percentage of participants with major adverse cardiovascular events (MACEs), including all-cause death, nonfatal myocardial infarction (MI), nonfatal stroke and coronary revascularization.
次要结局
- Percentage of participants with all-cause death(2021-2026)
- Percentage of participants with MI(2021-2026)
- Percentage of participants with stroke(2021-2026)
- Percentage of participants undergoing coronary revascularization(2021-2026)
- Change in BP control rate(2021-2026)
- Change in SBP(2021-2026)
- Change in estimated glomerular filtration rate (eGFR)(2021-2026)
- Change in low-density lipoprotein-cholesterol (LDL-c)(2021-2026)
- Percentage of participants with Metabolic dysfunction-associated steatotic liver disease (MASLD)(2021-2026)